Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Analyst Upgrades and Downgrades

SNDX has been the topic of several recent research reports. B. Riley reaffirmed a "buy" rating and set a $31.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, July 28th. StockNews.com cut Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, May 13th. Finally, The Goldman Sachs Group decreased their price objective on Syndax Pharmaceuticals from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Syndax Pharmaceuticals has an average rating of "Hold" and a consensus price target of $29.50.

Syndax Pharmaceuticals Trading Up 1.5 %

NASDAQ:SNDX traded up $0.37 during midday trading on Monday, hitting $24.37. 9,137 shares of the company traded hands, compared to its average volume of 586,660. The firm's fifty day moving average is $19.48 and its 200-day moving average is $17.47. Syndax Pharmaceuticals has a 12-month low of $13.27 and a 12-month high of $25.71. The firm has a market capitalization of $1.38 billion, a P/E ratio of 150.01 and a beta of 1.32. The company has a current ratio of 12.69, a quick ratio of 12.69 and a debt-to-equity ratio of 0.04.

Insider Activity at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 31,602 shares of the stock in a transaction on Monday, July 25th. The stock was sold at an average price of $21.06, for a total transaction of $665,538.12. Following the sale, the chief executive officer now owns 17,659 shares in the company, valued at approximately $371,898.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 31,602 shares of the stock in a transaction on Monday, July 25th. The stock was sold at an average price of $21.06, for a total value of $665,538.12. Following the sale, the chief executive officer now owns 17,659 shares in the company, valued at $371,898.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Briggs Morrison sold 62,292 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of $19.00, for a total value of $1,183,548.00. Following the completion of the sale, the insider now owns 17,836 shares in the company, valued at approximately $338,884. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,994 shares of company stock worth $1,851,186. Company insiders own 6.30% of the company's stock.